News

By granting standard review status to oritavancin, the FDA has established a target date to act on the new drug application (NDA) filing by December 8, 2008. The

These new data demonstrate ITI-007 has preclinical activity both in vitro and in vivo as an antidepressant. ITI-007 acts as a potent inhibitor of the serotonin transporter (SERT),

The cells called ‘parthenogenetic’ stem cells alleviate two critical problems inherent to the use of embryonic stem cells for cell transplantation, immune rejection and ethical issues associated with

Under the agreement, Merck will fund ongoing research in the laboratory of Laurie Glimcher, the Irene Heinz given professor of immunology at Harvard School of Public Health, and

The project has recently been awarded a public grant via the French Norwegian Foundation funded by the foundation, the French Ministry of Research and the French Innovation Society.

The research for this new drug started in 2000 and it is currently undergoing Phase I clinical trials in conjunction with the Chinese government’s State Food and Drug

Following a decision to focus its resources on its immunomodulatory compounds, Active Biotech has discontinued its participation in the I-3D co-development program and granted Chelsea exclusive global rights

Under the terms of the agreement, IntelGenx secured funding of $2 million for the completion of the product development after closing a private placement worth $2.8 million on

The Russian Ministry of Public Health registration was based on results from the largest, randomized, Phase III kidney cancer trial ever completed in the adjuvant treatment setting. Findings